Figure 5
From: Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Specific survival (cancer-related death) probability according to FCGR3A F158V gene polymorphism on the whole population. Median survival was 9.8 months in FF patients (29 patients, 21 events) vs 9.0 months in FV patients (20 patients, 15 events) vs 2.6 months in VV patients (6 patients, 6 events); Log Rank test: p < 0.001. Comparison of FF patients vs others was not significant (p = 0.31) whereas comparison of VV patients vs others gave a p value < 0.001.